Meridian Bioscience (Nasdaq:VIVO) - 주가, 뉴스 및 분석

VIVO 주식 개요

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. 자세한 내용

VIVO 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	0/6
과거 실적	1/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 25.5% 에서 거래

위험 분석

이익 마진 (12.7%) 작년보다 낮습니다 (22.5%)

재무 결과에 영향을 미치는 대규모 일회성 항목

Meridian Bioscience, Inc. 경쟁사

STAAR Surgical

NasdaqGM:STAA

US$1.3b

UFP Technologies

NasdaqCM:UFPT

US$2.2b

Embecta

NasdaqGS:EMBC

US$777.8m

Avanos Medical

NYSE:AVNS

US$768.3m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Meridian Bioscience
과거 주가
현재 주가	US$33.97
52주 최고치	US$34.38
52주 최저치	US$21.09
베타	0.23
11개월 변경	2.29%
3개월 변경 사항	6.02%
1년 변경 사항	54.34%
33년 변화	295.23%
5년 변화	128.75%
IPO 이후 변화	6,030.20%

최근 뉴스 및 업데이트

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27

주주 수익률

	VIVO	US Medical Equipment	US 마켓
7D	0.06%	-0.8%	-1.2%
1Y	54.3%	20.9%	30.4%

수익률 대 산업: VIVO 지난 1년 동안 20.9 %를 반환한 US Medical Equipment 산업을 초과했습니다.

수익률 대 시장: VIVO 지난 1년 동안 30.4 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is VIVO's price volatile compared to industry and market?
VIVO volatility
VIVO Average Weekly Movement	2.3%
Medical Equipment Industry Average Movement	7.9%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

안정적인 주가: VIVO 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: VIVO 의 주간 변동성( 2% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1976	704	Jack Kenny	www.meridianbioscience.com

Meridian Bioscience, Inc. 기본 사항 요약

Meridian Bioscience 의 수익과 매출은 시가총액과 어떻게 비교하나요?
VIVO 기본 통계
시가총액	US$1.49b
수익(TTM)	US$42.46m
수익(TTM)	US$333.02m

35.2x

P/E 비율

4.5x

P/S 비율

VIVO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
VIVO 손익 계산서(TTM)
수익	US$333.02m
수익 비용	US$144.66m
총 이익	US$188.36m
기타 비용	US$145.90m
수익	US$42.46m

최근 보고된 수익

Sep 30, 2022

다음 수익 날짜

n/a

주당 순이익(EPS)	0.96
총 마진	56.56%
순이익 마진	12.75%
부채/자본 비율	6.8%

VIVO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

VIVO 주식 개요

보상

위험 분석

Meridian Bioscience, Inc. 경쟁사

NasdaqGM:STAA

US$1.3b

NasdaqCM:UFPT

US$2.2b

NasdaqGS:EMBC

US$777.8m

NYSE:AVNS

US$768.3m

가격 내역 및 성능

최근 뉴스 및 업데이트

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in Vitro Diagnostic Manufacturers

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Recent updates

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in Vitro Diagnostic Manufacturers

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Independent Director exercised options to buy US$285k worth of stock.

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$34.00

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Consensus EPS estimates fall by 31%

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience: High-Probability Merger Arbitrage

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Bioscience: Correctly Valued

President exercised options and sold US$1.1m worth of stock

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience: Deceptively Priced

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

Price target increased to US$30.00

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Key Executive exercised options to buy US$157k worth of stock.

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Price target decreased to US$27.00

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Price target decreased to US$30.50

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Consensus forecasts updated

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021